Ambenonium

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Inhibits
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names

Europe

Czech Republic: Mytelase; France: Mytelase; Hungary: Mytelase; Poland: Mytelase; Sweden: Mytelase.

North America

USA: Mytelase.

Asia

Japan: Mytelase.

Drug combinations

Chemistry

Ambenonium Chloride: C~28~H~42~Cl~4~N~4~O~2~. Mw: 608.47. (1) Benzenemethanaminium, N,N’-[(1,2-dioxo-1,2-ethanediyl)bis(imino-2,1-ethanediyl)]bis[2-chloro-N,N-diethyl-, dichloride; (2) [Oxalylbis(iminoethylene)]bis[(o-chlorobenzyl)diethylammonium] dichloride. CAS-115-79-7; CAS-52022-31-8 (tetrahydrate); CAS-7648-98-8 (ambenonium).

Pharmacologic Category

Parasympathomimetic (Cholinergic) Agents. Anticholinesterases. (ATC-Code: N07AA30).

Mechanism of action

Therapeutic use

Treatment of myasthenia gravis.

Pregnancy and lactiation implications

Use in pregnant women requires that the possible benefits be weighed against the potential risks. Administration during lactation is not recommended.

Unlabeled use

Contraindications

Co-administration with atropine or other belladonna alkaloids. Patients receiving mecamylamine.

Warnings and precautions

Anticholinergic insensitivity may develop. Use with caution in asthma, bradycardia, hyperthyroidism, Parkinson’s disease, peptic ulcer disease, seizures or in urinary tract obstruction. Differentiation of cholinergic/myasthenia crisis is critical.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart